Lateral Flow Immunoassay for Rapid Whole-Blood ADA Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting anti-drug antibodies (ADA) in patients receiving biological therapies are labor-intensive, time-consuming, and not suitable for immediate clinical decision-making, particularly in autoimmune and inflammatory diseases, due to the need for specialized laboratories and complex sample preparation.
Innovation Solution
A rapid, portable, and cost-effective lateral flow immunoassay using an immunochromatographic system that allows almost instantaneous detection of ADA directly from whole blood samples without additional processing, utilizing a nitrocellulose membrane with immobilized biological drugs and detectably labeled conjugates, enabling on-site qualitative analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional laboratory methods are used for ADA detection, then measurement precision is improved, but loss of time and device complexity increase
Solution Approach 1:
The invention extracts the essential detection function from complex laboratory systems and implements it in a simplified lateral flow format. By taking out only the critical components (test line with immobilized biological drug, control line, and conjugate pad with labeled anti-human IgG) and removing unnecessary laboratory equipment requirements, the system achieves rapid results in minutes while maintaining adequate detection precision for clinical decision-making.
Solution Approach 2:
The invention changes the detection parameters by using a lateral flow immunoassay format with visual or instrumental readout instead of traditional ELISA or other laboratory-based methods. This parameter change enables the test to be completed in minutes rather than hours or days, while the use of detectably labeled conjugates maintains sufficient measurement precision for determining ADA presence and guiding treatment decisions.
2Measurement precision
If traditional laboratory methods are used for ADA detection, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The invention extracts the essential detection function from complex laboratory systems and implements it in a simplified lateral flow format. By taking out only the critical components (test line with immobilized biological drug, control line, and conjugate pad with labeled anti-human IgG) and removing unnecessary laboratory equipment requirements, the system achieves rapid results in minutes while maintaining adequate detection precision for clinical decision-making.
Solution Approach 2:
The lateral flow strip is designed as a self-contained system that performs sample processing, antigen-antibody interaction, and result visualization without requiring external laboratory equipment or complex operational procedures. The sample automatically wicks through the membrane via capillary action, bringing it into contact with the conjugate and test line, and the result appears visually or can be read with simple instrumentation, making the system self-sufficient and easy to use.
3Loss of time
If rapid detection is implemented, then loss of time is reduced, but measurement precision may worsen
Solution Approach 1:
The invention performs preliminary action by pre-immobilizing the biological drug on the test line and pre-labeling the anti-human IgG with detectable labels in the conjugate pad during manufacturing. This preliminary preparation eliminates the need for time-consuming sample processing steps during actual testing, allowing rapid detection while maintaining precision because the critical reagents are already in their functional states before the test is performed.
Solution Approach 2:
The invention uses detectably labeled anti-human IgG as an intermediary that bridges the sample (patient serum containing ADA) and the test line (immobilized biological drug). This intermediary conjugate enables rapid detection by forming visible complexes that can be read quickly, while the specific antibody-antigen binding ensures measurement precision. The label acts as a mediator that translates the biochemical interaction into a rapidly detectable signal.
4Ease of operation
If simplified sample processing is used, then ease of operation is improved, but measurement precision may worsen
Solution Approach 1:
The lateral flow strip is designed as a self-contained system that performs sample processing, antigen-antibody interaction, and result visualization without requiring external laboratory equipment or complex operational procedures. The sample automatically wicks through the membrane via capillary action, bringing it into contact with the conjugate and test line, and the result appears visually or can be read with simple instrumentation, making the system self-sufficient and easy to use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Facilitates immediate clinical decisions on biological drug dosing by simplifying the detection process, reducing resource requirements, and allowing frequent monitoring of ADA levels for personalized treatment adjustments.
Implementation Method 1
a membrane or test strip comprising: a sample pad where the sample to be tested for the presence of ADA is applied (1); a conjugate pad wherein detectably labeled biological drug is placed (2); a nitrocellulose membrane with a flow direction from the sample pad to the conjugate pad (3)
Implementation Method 2
a capture area comprises said biological drug immobilized thereto. The bridge binding format wherein the ADA, if present in the sample of the patient, acts a bridge binding both the detectably labeled biological drug in the conjugate area and the biological drug immobilized in the capture area
Data Source
AI summary
A lateral flow immunoassay for the detection of anti-drug antibodies against a biological drug includes a membrane having a capture area, a sample application area, a flow path from the sample application area to the capture area, and a conjugate area located in the flow path. The conjugate area has said biological drug detectably labeled and the capture area has said biological drug immobilized thereto.